이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

DLBCL의 DPX-Survivac 및 체크포인트 억제제 (SPiReL)

2026년 8월 31일 업데이트: Sunnybrook Health Sciences Centre

지속성 또는 재발성/불응성 미만성 거대 B세포 림프종(DLBCL) 환자를 대상으로 펨브롤리주맙과 함께 저용량 시클로포스파미드를 투여한 면역 요법, DPX-Survivac의 2상 연구

This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two months with low dose metronomic oral cyclophosphamide (50 mg BID) for one year or until disease progression, whichever occurs first.

Pembrolizumab 200 mg will be administered every 3 weeks for up to one year or until disease progression, whichever occurs first.

연구 개요

상세 설명

This is a Phase 2, non-randomized, open-label, uncontrolled, efficacy and safety trial.

Participants will receive 2 priming injections (0.5ml) of DPX-Survivac 3 weeks apart on Study Days 7 and 28. In addition, up to 6 maintenance injections (0.1ml) over the course of the study occurring on Study Days 84, 140, 196, 252, 308, and 364. All injections will be given under the skin of the upper thigh.

Participants will receive metronomic oral cyclophosphamide (50mg BID; 7 days on / 7 days off) for study period.

Pembrolizumab 200mg will be administered intravenously every 3 weeks, commencing on study day 7, to a total of 18 infusions.

If a participant is removed from the trial prior to the completion of at least 4 doses of Pembrolizumab and 3 injections of DPX-Survivac, that particiapnt may be replaced to determine the efficacy of treatment in a minimum of 16 participants.

DPX-Survivac injection sites will be evaluated throughout the study and if evidence of significant reaction, an Injection site reaction biopsy will be sought.

During the course of the study, blood will be drawn to evaluate immune cells and the effect that DPX Survivac will have on the participants immune system. During all treatment cycles a physical exam and questions about the participants general health will be performed.

Participants will undergo "re-staging" to assess the status of their disease at approximately study day 70 (if there is evidence of Grade 2 or greater injection site reaction or ulceration evident on study day 49) or routinely at approximately study day 91, and again at end of study or study withdrawal for all participants.

A follow-up tumour biopsy will be requested between study day 77-83 for participants with any grade 2 or greater Injection site reaction or ulceration on SD49 or between SD98 and SD104 if no evidence of injection site reaction or ulceration.

Upon completion of study, participants will be monitored every 2 months for 1 year.

연구 유형

중재적

등록 (실제)

25

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Alberta
      • Calgary, Alberta, 캐나다
        • Tom Baker Cancer Centre - Alberta Health Services
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다, B3H 2Y9
        • Nova Scotia Health Authority: Queen Elizabeth II Health Sciences Centre
    • Ontario
      • London, Ontario, 캐나다, N6A 5W9
        • London Health Sciences Centre
      • Ottawa, Ontario, 캐나다
        • Ottawa Hospital Research Institute
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Sunnybrook Health Sciences Centre, Odette Cancer Centre
    • Quebec
      • Montreal, Quebec, 캐나다
        • McGill University Health Centre

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria

In order to be eligible for participation in this trial, the subject must:

  1. Be willing and able to provide written informed consent/assent for the trial.

  2. Male or female 18+ years of age on day of signing informed consent and of any racial or ethnic group

  3. Has:

    A. histologically proven DLBCL with recurrence after first, second or tertiary treatment regimens for DLBCL or,

    B. evidence of transformed lymphoma with past history of indolent lymphoma with current biopsy showing DLBCL) or,

    C. double hit or high grade lymphomas, including Burkitts lymphoma and High Grade B-Cell lymphoma unclassifiable (with features intermediate between Burkitts and diffuse large B cell lymphoma)

  4. Has had:

    A. recurrence requiring therapy at least 90 days post aggressive first line combination chemotherapy (e.g. RCHOP, Hyper-CVAD or other aggressive "curative" combination), autologous stem cell transplantation (ASCT), CART therapy, or aggressive second line combination therapy or,

    B. partial response or measureable disease after first line therapy (who are not candidates for ASCT) or after second or third line therapy without disease progression or,

    C. recurrence any time after non-aggressive combination or single agent therapy with or without Rituximab (i.e. CVP, CHL or, VP16) for first, second or third line disease or,

    D. for subjects with transformed lymphoma, a treatment for indolent lymphoma within the last 2 years

  5. Have at least one measurable site of disease based on Cheson Criteria using standard CT imaging.

  6. Be willing to provide tissue from a newly obtained (up to 3 months + 7 days prior to Study Day 0) biopsy of a tumour lesion. If this is not available, the patient must be willing to undergo a core biopsy prior to starting treatment. They must also be willing to provide an on-treatment biopsy.

  7. Have a performance status of 0-1 on the ECOG Performance Scale.

  8. Demonstrate adequate organ function as defined in Table 2, within 48 hours prior to receiving the first dose of study medication (SD0). Patients with abnormal liver enzymes of up to 5 times the upper limit of normal and/or reduced GFR of 50-100% normal range can be considered for enrolment if the alteration is due to lymphoma.

  9. Previous localized surgery, radiotherapy, chemotherapy, and immunotherapy more than 21 days prior to SD0. Cyclophosphamide, up to 100 mg/day, may be administered until SD-1 for subjects already receiving as a single agent therapy.

  10. A life expectancy > 6 months.

  11. Female subject of childbearing potential should have a negative urine or serum pregnancy within 48 hours prior to receiving the first dose of study medication (SD0). If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

  12. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.

  13. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through to 120 days from the last dose of study medication.

  14. Ability to comply with protocol requirements.

Exclusion Criteria

The subject must be excluded from participating in the trial if the subject:

  1. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 21 days of the first dose of treatment (SD0).
  2. Patients eligible for possible curative therapies such as ASCT.
  3. LDH greater than 5 times the upper limit of normal.
  4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 35 days prior to the first dose of trial treatment (SD0), except that used as pre-medication for chemotherapy or contrast-enhanced studies are eligible. Subjects may be on physiologic doses of replacement prednisone or equivalent doses of corticosteroid (<10 mg daily).
  5. Has had previous allogeneic stem cell transplant
  6. Has known active TB (Bacillus Tuberculosis)
  7. Hypersensitivity to pembrolizumab or any of its excipients.
  8. Has had a prior anti-cancer monoclonal antibody (mAb) within 21 days prior to SD0 or who has not recovered (i.e., ≤ Grade 1) from adverse events due to agents administered more than 21 days earlier.
  9. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 21 days prior to SD0. Subjects must have recovered from all acute toxicities from prior treatments; peripheral neuropathy must be ≤ grade 2.
  10. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include in situ cervical cancer, basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy.
  11. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided; they are stable (without evidence of progression by imaging) for at least four weeks prior to the first dose of trial treatment; and any neurologic symptoms have returned to baseline; have no evidence of new or enlarging brain metastases; and are not using steroids for at least 35 days prior to trial treatment.
  12. Progressive CNS lymphoma requiring treatment within 35 days prior to SD0.
  13. Has history of active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  14. Has known history of, or any evidence of active, non-infectious pneumonitis.
  15. Thyroiditis within the past 5 years.
  16. Has an active infection requiring systemic therapy. Subjects completing a course of antibiotic for acute infection 7 days prior to SD0 and who do not experience a recurrence of symptoms or fever are eligible.
  17. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  18. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  19. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with screening visit to 120 days after last dose of study medication.
  20. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
  21. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
  22. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected). Evidence of Hepatitis B surface antigen without transaminitis is allowed provided patient is treated with anti-viral therapy (Heptavir or Tenofovir).
  23. Patients who have received prior survivin based vaccines.
  24. Acute or chronic skin disorders that will interfere with subcutaneous injection of the DPX-Survivac or subsequent assessment of potential skin reactions.
  25. Serious intercurrent chronic or acute illness, such as cardiac disease (New York Heart Association class III or IV), hepatic disease, or other illness considered by the investigator as an unwarranted high risk for an investigational product.
  26. Allergies to any vaccine, that after discussion with the medical monitor are serious enough to warrant exclusion from this study.
  27. Received a live vaccine within 30 days of planned start of study therapy. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Single Arm-Investigational

DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.

Pembrolizumab 200mg Intravenously.

Cyclophosphamide 50mg Twice daily orally.

DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.

Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions

Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Objective Response Rate Using Modified Cheson Criteria to Treatment With DPX-Survivac and Low Dose Cyclophosphamide Administered Together With Pembrolizumab in Participants With Recurrent, Survivin-expressing B Cell Lymphomas
기간: 1 Year

Objective Response Rate is the combined Complete Response (CR) and Partial Response (PR) rates using Cheson Criteria (2007) for evaluation. Site Qualified Investigators use radiological reports to calculate the decrease in tumour size from baseline at protocol specified time points.

1 Year

2차 결과 측정

결과 측정
측정값 설명
기간
Duration of Response Using Modified Cheson Criteria.
기간: 2 Years

Completing response assessment post radiology using the Cheson criteria

2 Years
Time to Next Treatment
기간: 42 months

time lapse between current and next treatment

42 months
Evidence of Regression Using Waterfall Analyses
기간: 1 year

Waterfall analysis is describing visually the participants best clinical response using the Modified Cheson Criteria (2007) and irRC (immune related response criteria). This includes Complete (CR), Partial (PR), Stable disease (SD) and Progressive Disease (PD). Participants are then categorized by their PD-L1 bio-marker response to show their tumour size decrease (in %) from baseline to their best response. Overall Response Rate (ORR) = CR+PR. Disease Control Rate (DCR) = CR+PR+SD.

1 year
Toxicity Profile
기간: 1 year

Safety will be assessed through patient reported and investigator observed Adverse Events (AE's) and graded using CTCAE version 4.03. This will also include physical examination and clinical laboratory tests. Specific attention will be placed upon injection site reactions and potential immune mediated AE's. Reporting will be on all AE's, regardless of relatedness, causality or severity and will include and AE's recorded from the time of participant consent to 30 days after treatment completion, resolution or lost-to-follow-up. Injection site reactions will be documented as grades of erythema, induration, pain, edema, ulceration or other. See Adverse Event section below for details.

1 year

기타 결과 측정

결과 측정
측정값 설명
기간
Changes in Circulating T Cell Immune Responses to Survivin and Relationship to Peripheral B Cell Numbers
기간: 1 year

Therapy with DPX-Survivac is expected to increase the frequency and activity of survivin-specific anti-tumour T cells. Survivin-peptide specific T cell immune response will be measured by methods such as ELISpot assay to enumerate T cells that produce molecules associated with anti-tumour immune responses such as IFN-γ and/or Granzyme-B. Additional immunological assays such as MHC-peptide multimer staining for survivin-specific CD8+ T cells, or multi-parametric flow cytometry for antigen-activated T cells and their phenotypes may also be performed for select subjects. Other exploratory immunologic assessments may be performed on frozen PBMC samples and subject plasma/serum if a novel method becomes available during the course of the study.

1 year
Changes in T Cell and T Cell Subset Infiltration and Gene Expression Pathways in Treatment Compared to Pre-treatment Tumour Biopsies
기간: 1 year

Therapy with DPX-Survivac is expected to increase the frequency and activity of survivin-specific anti-tumour T cells. Survivin-peptide specific T cell immune response will be measured by methods such as ELISpot assay to enumerate T cells that produce molecules associated with anti-tumour immune responses such as IFN-γ and/or Granzyme-B. Additional immunological assays such as MHC-peptide multimer staining for survivin-specific CD8+ T cells, or multi-parametric flow cytometry for antigen-activated T cells and their phenotypes may also be performed for select subjects. Other exploratory immunologic assessments may be performed on frozen PBMC samples and subject plasma/serum if a novel method becomes available during the course of the study.

1 year
Assess Potential Biomarkers of Immune and Clinical Response From Subject Clinical, Biological and Immunologic Data From Pre-treatment and On-treatment Tumour Biopsies
기간: 1 year

Tumour-specific T cells must migrate to the tumour site to mediate anti-tumour activity. We will quantitate changes in T cell infiltration and the expression profile of this T cells in tumour sites before and during treatment.

1 year
Relevant Biologic Assays That May be Identified During the Conduct of the Trial That May Have Immune or Clinical Relevance on Samples Already Collected
기간: 1 year

This will be determined at a later date

1 year

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Neil L Berinstein, MD, Sunnybrook Research Institute

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 3월 13일

기본 완료 (실제)

2021년 10월 31일

연구 완료 (실제)

2023년 7월 18일

연구 등록 날짜

최초 제출

2017년 11월 14일

QC 기준을 충족하는 최초 제출

2017년 11월 16일

처음 게시됨 (실제)

2017년 11월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 31일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

For original data, contact SPiReL@sunnybrook.ca. Individual patient data will be de-identified, however, data can be shared for a period of up to 5 years after trial closure with formal Confidentiality and Data Transfer agreements in place as appropriate.

A data dictionary will not be shared, the Statistical Analysis Plan can be made available with publication.

IPD 공유 기간

Up to 5 years after the closure of the trial

IPD 공유 액세스 기준

contact SPiReL@sunnybrook.ca

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다